Activated hepatic stellate cells with senescence-associated secretory phenotype signature in steatohepatitic hepatocellular carcinoma by �씠吏��궛
  
 
Activated hepatic stellate cells with 
senescence-associated secretory phenotype 
signature in steatohepatitic hepatocellular 
carcinoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jee San Lee 
Department of Medical Science 
The Graduate School, Yonsei University 
 Activated hepatic stellate cells with 
senescence-associated secretory 
phenotype signature in steatohepatitic 
hepatocellular carcinoma 
 
 
 
 
Directed by Professor Young Nyun Park 
 
 
 
The Master's Thesis  
submitted to the Department of Medical Science, 
the Graduate School of Yonsei University 
in partial fulfillment of the requirements for the degree of 
Master of Medical Science 
 
 
Jee San Lee 
 
 
 
 
 
December 2014 
 
 
 
 
 This certifies that the Master's Thesis of 
Jee San Lee is approved. 
 
 
 
---------------------------------------------- 
Thesis Supervisor: Young Nyun Park 
 
---------------------------------------------- 
Thesis Committee Member#1: Jin Sub Choi 
 
---------------------------------------------- 
Thesis Committee Member#2: Haeryoung Kim 
 
 
 
 
 
 
The Graduate School  
Yonsei University 
 
 
 
December 2014 
  
ACKNOWLEGEMENTS 
먼저, 이 논문이 완성되기 까지 많이 부족했던 저에게 아낌없는 지도, 
격려, 인내 그리고 배려를 해주신 박영년 교수님께 깊은 감사드립니다. 
그리고 제 논문을 지도해 주시고 많은 조언을 해주신 최진섭 교수님, 
김혜령 교수님께 감사의 말씀 드립니다.  
또한, 이 논문이 완성되기 까지 너무나 많은 도움을 주신 병리학교실 
분들께 감사의 말씀 드립니다. 면역염색 및 면역형광 염색을 잘 세팅할수 
있도록 도와주고 항상 격려해 주신 유정은 선생님, 환자 데이터 및 
분석에 많은 도움을 주시고 다방면으로 도와주셨던 이형진 선생님, 이 
논문의 큰 틀을 잡아주신 고명주 선생님, 면역 염색 분석 및 병리 분석 
방법을 차근차근 알려주신 남지해 선생님, 슬라이드를 깎아주시고 항상 
진심 어린 조언을 주셨던 방근배 선생님, 블록을 찾아주신 차종훈 선생님, 
염색 방법 및 실험 방법에 많은 조언을 주신 오성근, 박원영 선생님, 
많은 격려를 해주신 김영주 선생님, 그리고 언니이자 동기이고 친구 같은 
나의 모든걸 이해해준 그리고 나에게 정말 아낌없었던 고정은 선생님, 
모두에게 너무나 많은 감사드립니다. 선생님들의 도움이 없었으면 이 
논문은 없었을 것입니다. 그리고 마지막으로 항상 옆에서 나를 응원해 
주었던 친구들에게 너무 고맙고 끝없이 응원을 해준 우리 가족과 
친척분들께 감사의 말씀을 전하고 싶습니다.    
 
이지산 
 
 
 <TABLE OF CONTENTS> 
ABSTRACT .................................................................................................... 1 
I. INTRODUCTION ........................................................................................ 3 
II. MATERIALS AND METHODS ................................................................. 5 
1. Case selection and histopathological examination .................................. 5 
2. Immunohistochemistry and immunofluorescence ................................... 7 
3. Interpretation of staining results .............................................................. 9 
4. DNA extraction and HBV DNA nested PCR ........................................ 10 
5. Total RNA extraction, cDNA synthesis, and real-time quantitative 
reverse-transcriptase PCR.......................................................................... 12 
6. Statistical analyses ................................................................................. 13 
III. RESULTS ................................................................................................ 13 
1. Pathological definition and selection of steatohepatitic HCC ............ 13 
2. Other pathological characteristics of steatohepatitic HCC ................ 16 
3. Clinical characteristics in steatohepatitic and conventional HCCs .... 18 
4. Increased numbers of activated hepatic stellate cells in steatohepatitic 
HCC ........................................................................................................ 20 
5. Increased numbers of activated hepatic stellate cells, expressing 
senescence-associated proteins and senescence-associated secretory 
phenotype (SASP) factor in the tumor region of steatohepatitic HCC .. 22 
6. Senescent-associated proteins and senescence-associated secretory 
phenotype (SASP) factor in activated hepatic stellate cells in the non-
 tumor region of steatohepatitic and conventional HCCs and normal 
control livers ........................................................................................... 27 
7. Survival analysis in steatohepatitic and conventional HCCs ............. 32 
IV. DISCUSSION .......................................................................................... 32 
V. CONCLUSION ......................................................................................... 35 
REFERENCES ............................................................................................. 36 
 ABSTRACT (IN KOREAN) ........................................................................ 40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 LIST OF FIGURES 
 
Figure 1. Histopathological features of steatohepatitic and 
conventional HCCs∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙14 
Figure 2. Activated hepatic stellate cells are increased in the tumor 
region of steatohepatitic HCC∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙21 
Figure 3. Increased numbers of activated hepatic stellate cells 
expressing senescence-associated proteins and senescence 
 -associated secretory phenotype (SASP) factor in the tumor 
region of steatohepatitic HCC∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙24 
Figure 4. Senescence-associated proteins in the tumoral hepatocytes 
of steatohepatitic and conventional HCCs∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙ 
  ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙26  
Figure 5. Senescence-associated proteins and senescence-associated  
 secretory phenotype (SASP) factor in the activated hepatic 
stellate cells in the non-tumor region of steatohepatitic 
and conventional HCCs∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙28 
Figure 6. Senescence-associated proteins in the non-tumoral 
hepatocytes of steatohepatitic and conventional HCCs∙∙∙∙∙∙∙∙  
  ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙30  
Figure 7. Senescence-associated proteins and senescence-associated 
 secretory protein (SASP) factor in the normal control liver 
∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙31  
Figure 8. Survival analysis results∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 LIST OF TABLES 
 
Table 1. List of antibodies used for immunohistochemistry and 
immunofluorescence ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙8 
Table 2. Sequences of the primers used for the HBV DNA nested 
PCR ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙11 
Table 3. A comparison of the histopathological features between 
steatohepatitic and conventional hepatocellular carcinomas 
   ∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙15 
Table 4. Pathological characteristics of steatohepatitic and 
conventional hepatocellular carcinomas∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙17 
Table 5. Clinical characteristics of patients with steatohepatitic and 
conventional hepatocellular carcinomas∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙∙19 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
 
<ABSTRACT> 
 
Activated hepatic stellate cells with senescence-associated secretory 
phenotype signature in steatohepatitic hepatocellular carcinoma 
 
Jee San Lee 
 
Department of Medical Science 
The Graduate School, Yonsei University  
 
(Directed by Professor Young Nyun Park) 
 
Steatohepatitic hepatocellular carcinoma (HCC), a new histologic variant of HCC 
has been recently reported in patients with metabolic syndrome or hepatitis C virus–
related cirrhosis with associated non-alcoholic fatty liver disease (NAFLD). The 
incidence of metabolic syndrome has rapidly increased in Asia including Korea, 
where hepatitis B virus (HBV) is the main etiology of HCC. However, 
clinicopathological features of steatohepatitic HCC in HBV patients with metabolic 
syndrome and its molecular pathogenesis remain unclear. Steatohepatitic HCCs (n = 
21) and conventional HCCs (n = 34) were selected from non-C viral, non-alcoholic 
and non-autoimmune hepatitis patients, and the HBV infection was evaluated by 
serological test of HBsAg or HBV DNA nested PCR using liver tissue. Their 
difference in clinical, and molecular pathological aspects was analyzed focusing 
hepatic stellate cell activation and senescence-associated secretory phenotype 
(SASP). The expression of α-smooth muscle actin (α-SMA), p21Waf1/Cif1, γ-H2AX, 
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IL-6, and Ki-67 were investigated by single or double immunohistochemistry or 
immunofluorescence. Steatohepatitic HCCs showed significantly older age, higher 
body mass index, higher incidence of diabetes, central obesity, hypertriglyceridemia 
and NAFLD compared to conventional HCCs (P <0.05 for all). Metabolic 
syndrome was more prevalent in steatohepatitic HCCs compared to conventional 
HCCs (P= 0.029), whereas the incidence of HBV infection showed no significant 
difference between two groups. Activated hepatic stellate cells expressing 
p21
Waf1/Cif1
, IL-6 (P <0.05 for both) and γ-H2AX (P = 0.066) were more frequently 
found in steatohepatitic HCCs compared to conventional HCCs. Non-tumoral liver 
of steatohepatitic HCCs also showed higher number of activated stellate cells 
expressing γ-H2AX and p21Waf1/Cif1 compared to that of conventional HCCs (P 
<0.05 for both). There was no significant difference of Ki-67 expressing activated 
hepatic stellate cells between steatohepatitic and conventional HCCs in both of 
tumoral and non-tumoral lesions.  
Therefore, steatohepatitic HCC is suggested as a distinctive variant of HCC in 
metabolic syndrome with or without chronic B viral hepatitis. Activated hepatic 
stellate cells expressing senescence-associated protein (p21
Waf1/Cif1
 and γ-H2AX) 
and SASP factor (IL-6) are considered to be important in the pathogenesis of 
steatohepatitic HCC. 
 
 
 
Key Words: hepatocellular carcinoma, steatohepatitic hepatocellular carcinoma, 
non-alcoholic fatty liver disease, metabolic syndrome, activated hepatic stellate 
cells, senescence-associated secretory phenotype 
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I. INTRODUCTION 
 
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of fatty liver 
diseases, ranging from simple steatosis, to non-alcoholic steatohepatitis, fibrosis, 
and ultimately cirrhosis
1,2
. The incidence of hepatocellular carcinoma (HCC) is 
increasing gradually in association with metabolic syndrome
3, 4
.The prevalence of 
metabolic syndrome is increasing in Asia including in Korea
5
. Obesity together with 
diabetes, also increase the risk of HCC development to approximately 100 fold in 
patients with hepatitis C virus (HCV) and hepatitis B virus (HBV)
6
.  
Recently, a histologically distinct subtype of HCC showing features of 
steatohepatitis within the tumor region has been pathologically characterized and 
introduced as a new category, termed steatohepatitic HCC
7
. This newly defined 
HCC variant histologically resembles non-neoplastic steatohepatitis, characterized 
by large droplet steatosis in tumor cells, pericellular fibrosis, inflammation, 
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ballooning, and Mallory-Denk body formation. In addition, steatohepatitic HCC 
variant is associated with metabolic syndrome
7-9
. Most studies about steatohepatitic 
HCC have mainly dealt with HCC patients with HCV, and the clinicopathological 
features of steatohepatitic HCC in HBV patients - which is the main etiology of 
HCC in Asia including Korea - remains unclear
10
.  
The activation of hepatic stellate cells in chronic liver disease including NAFLD 
has been demonstrated in association with several conditions, including fatty change, 
reactive oxygen species generation and DNA damage etc
11
. In response to these 
stimuli, hepatic stellate cells undergo phenotypic conversion from quiescent 
retinoid-storing cells to active myofibroblastic cells and ultimately affect fibrosis 
progression
12
. Interestingly, dietary or genetically-induced obesity in mice led to 
alterations in intestinal microbiomes and deoxycholic acid (DCA) production, 
which in turn induced senescence-associated secretory phenotype (SASP) in hepatic 
stellate cells and promoted obesity-associated HCC development
13
. This study 
demonstrated that senescence-associated markers such as p21, p16 and γ-H2AX 
were up-regulated in the tumor region, particularly in the activated hepatic stellate 
cells and these cells produced SASP factors
13
. In steatohepatitic HCCs increased 
number of activated hepatic stellate cells were observed, however its relation with 
SASP factors have not been demonstrated
8
. In the present study, clinicopathological 
features of steatohepatitic HCC in metabolic syndrome with HBV and its molecular 
pathogenesis was investigated focusing on the hepatic stellate cell activation and 
senescence associated protein and SASP factor including p21
Waf1/Cif1,γ-H2AX, Ki-
67 and IL-6. 
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II. MATERIALS AND METHODS 
 
1. Case selection and histopathological examination 
 
We reviewed the pathological and clinical records of consecutive HCC patients who 
underwent partial hepatectomy or liver transplantation between 2009 and 2014, 
from the archives of the Department of Pathology, Yonsei University College of 
Medicine. Patients who underwent chemotherapy or locoregional therapy (such as 
transarterial chemoembolization or radioactive frequency ablation) before surgery 
were excluded from this study. We excluded patients with histories of excessive 
alcohol consumption (defined as >40 g/day), viral hepatitis C, D and E, and 
autoimmune disease. The status of hepatitis B virus surface antigen (HBsAg) was 
reviewed. Formalin-fixed, paraffin-embedded tissue sections stained with 
hematoxylin-eosin (H&E) and Masson‟s trichrome were reviewed for all cases. 
When multiple tumors were present, the largest tumor was selected for assessment. 
The histopathologic characteristics of each HCC was assessed and recorded, 
especially focusing on features of steatohepatitis as follows
8
; 1) large-droplet fat 
within the tumor: absent/minimal (0% to 4%), mild (5% to 33%), moderate (34% to 
60%) and severe (>60%); 2) ballooning change: none, focal, marked ; 3) Mallory-
Denk bodies: absent, present ; 4) pericellular fibrosis: thin strands of fibrosis with a 
“chicken-wire” appearance: none, focal, marked ; 5) inflammation, including 
neutrophils and lymphocytes: minimal (<2 foci of inflammatory cells under the 10x 
objective), mild (2 to 5 foci of inflammatory cells under the 10x objective), and 
moderate (>5 foci of inflammatory cells under the 10x objective). Steatohepatitic 
HCCs was selected based on the following criteria: a combination of at least four of 
the above features in ≥50% of the tumor area. For comparison, conventional HCCs 
which have typical histopathological features of HCCs were selected. For normal 
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control liver, 5 non-neoplastic liver samples from liver donors or non-neoplastic 
livers adjacent to metastatic carcinomas were used. The control samples were 
negative for HBV and showed relatively normal liver histology.  
Other histopathological features of each case, including size, capsule formation, 
major and worst grades of differentiation, and presence of vascular invasion were 
also noted. The non-tumor liver was assessed and scored for steatosis and evidence 
of steatohepatitis. The degree of steatosis in the parenchyma was classified as 
absent/minimal (0% to 5%), mild (6% to 30%), moderate (31% to 60%), and severe 
(>60%) 
14
. In addition, according to the US National Cholesterol Education 
Program Adult Treatment Panel III (NCEP ATP III, 2001) and International 
Diabetes Federation (IDF) ethnicity waist circumference criteria, we reviewed the 
clinical charts for the presence of metabolic syndrome risk factors: central obesity 
[waist circumference >90 cm in men and >80 cm in women and body mass index 
(BMI)], hypertriglyceridemia [serum triglycerides (≥150 mmHg) or current use of 
antidyslipidemia medication], low high-density lipoprotein cholesterol [(<40 mg/dL) 
in men and (<50 mg/dL) in women], diabetes [elevated fasting plasma glucose 
levels (≥100 mg/dL) or current use of anti-diabetic medication] and hypertension 
[systolic blood pressure (≥130 mmHg) or diastolic blood pressure (≥85 mmHg) or 
current use of blood pressure medication]
15, 16
. 
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2. Immunohistochemistry and immunofluorescence  
 
Formalin-fixed paraffin-embedded tissues were cut into 4µm-thick sections. The 
paraffin embedded sections were deparaffinized for an hour and rehydrated in 
graded alcohol and in distilled water for 1 minute each at room temperature. For 
immunohistochemistry, sections were soaked in 3% H202 for 15 minutes to block 
the endogenous peroxidase. After washing, antigen retrieval was performed. A 
complete list of the primary antibodies used and the antigen retrieval conditions are 
described in Table 1. The primary antibody IL-6 was applied to the slide and 
incubated for an hour at room temperature. After rinsing, incubation with a 
secondary antibody was performed for 20 minutes using DAKO Envision kit (Dako, 
Glostrup, Denmark), and visualized with 3,3-diaminobenzidine (DAB). Sections 
were counterstained with Mayer‟s hematoxylin for 7 minutes and rinsed in tap 
water for 20 minutes. Slides were then dehydrated and mounted. For the double 
immunohistochemistry [alpha-smooth muscle actin (α-SMA) and p21Waf1/Cip1], 
p21
Waf1/Cip1
 primary antibody was applied to the slides, left overnight in 4 °C, and 
then treated with Vector Blue Alkaline Phosphatase Substrate Kit III (SK-5300; 
Vector Laboratories, Burlingame, CA, USA). Next, α-SMA (Dako, Glostrup, 
Denmark) primary antibody was applied for an hour at room temperature. 
Secondary antibody was applied using the DAKO Envision kit, and then developed 
with DAB. Double immunofluorescence was carried out to assess the 
phosphorylation of histone H2AX at ser139 (γ-H2AX) and the expression levels of 
Ki-67 and IL-6 in activated hepatic stellate cells. After deparaffinization and 
rehydration as described above, sections were soaked twice in 1%NaHB4 for 5 
minutes each to block the endogenous peroxidase. Before staining for γ-H2AX/α-
SMA (Dako, Glostrup, Denmark) and Ki-67/α-SMA (Abcam, Cambridge, MA, 
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USA) sections were pretreated in 10mM citrate buffer (pH6.0) in a microwave for 
20min for antigen retrieval. Blocking step was followed for 30 minutes using 
5%BSA, and two primary antibodies raised in different species [γ-H2AX/α-SMA 
(Dako, Glostrup, Denmark), IL-6/α-SMA (Dako, Glostrup, Denmark) and Ki-67/α-
SMA (Abcam, Cambridge, MA, USA)] were applied to the slides. After rinsing the 
primary antibody, Alexa fluor 594 (red) goat anti rabbit IgG and Alexa fluor 488 
(green) donkey mouse IgG conjugated antibodies (Invitrogen, Carlsbad, CA, USA) 
were applied for 60 minutes. The slides were washed in the dark and nuclei were 
stained with 4‟-6‟ diamidino-2-phenylindole (Life Technologies, Gaithersburg, MD, 
USA) and left to dry for 2 days in the dark before imaging in the microscope. For 
ubiquitin, an XT automated stainer (Ventana, Tucson, AZ, USA) was used. 
Table 1. List of antibodies used for the immunohistochemistry and 
immunofluorescence 
Antibody Source Dilution Antigen retrieval 
α-SMA (mouse mAb; clone 1A4) 
Dako  
(Glostrup, Denmark) 
1:1000 
Microwave, citrate (pH 6.0) 
or no treatment 
α-SMA (rabbit pAb)  
Abcam  
(Cambridge, MA, USA) 
1:300 
Microwave, citrate 
 (pH 6.0) 
p21Waf1/Cip1 (rabbit mAb; 12D1) 
Cell signaling (Danvers, 
MA, USA) 
1:50 
Microwave, citrate  
(pH 6.0) 
γ-H2AX (rabbit mAb; 20E3) 
Cell signaling (Danvers, 
MA, USA) 
1:150 
Microwave, citrate  
(pH 6.0) 
IL-6 (rabbit pAb) 
Abcam  
(Cambridge, MA, USA) 
1:100 Protease K or no treatment 
Ki-67 (mouse mAb; MIB-1) 
Dako  
(Glostrup, Denmark) 
1:100 
Microwave, citrate 
 (pH 6.0) 
Ubiquitin (rabbit pAb) 
Dako 
(Glostrup, Denmark) 
1:200 
Microwave, citrate 
 (pH 6.0) 
Abbreviations: α-SMA, α-smooth muscle actin; mAb, monoclonal antibody; pAb, polyclonal antibody 
* No treatment for immunofluorescence 
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3. Interpretation of staining results 
 
The immunohistochemical stain results for IL-6 and p21
Waf1/Cip1
 (nuclear staining in 
tumoral and non-tumoral hepatocytes) was assessed. The staining intensity was 
graded on a scale of 0~3 (0, negative; 1, weakly positive; 2, moderately positive; 
and 3, strongly positive), and the extent of distribution was rated on a scale of 0~4 
(0, positive in <5% of cells; 1, 5~25%; 2, 26~50%; 3, 51~75%; and 4, 76~100%). 
The histoscore was defined as the sum of the intensity and distribution scores. 
Positive staining was defined as staining scores of 4~7 whereas 0~3 were regarded 
as negative. To assess the number of activated hepatic stellate cells, 20 
photomicrographs were taken at original magnification x400 then the α-SMA 
positive cells were counted for each picture. α-SMA expressed in the blood vessels 
or bile ducts were excluded. For the p21
Waf1/Cip1/α-SMA co-stained cells, the number 
of α-SMA positive cells and p21Waf1/Cip1/α-SMA co-stained cells were counted in 20 
randomly selected fields (original magnification x400). The average number for 
p21
Waf1/Cip1/α-SMA co-stained cells were calculated by dividing total number of 
p21
Waf1/Cip1/α-SMA co-stained cells by the total number of α-SMA positive cells and 
multiplied by 100%. For the γ-H2AX/α-SMA, IL-6/α-SMA and Ki-67/α-SMA co-
stained cells, at least 100 α-SMA positive cells were counted at original 
magnification x200 and the average number of co-stained cells was calculated as 
described above. The presence or absence of Mallory-Denk bodies were evaluated 
by immunoreactivity for ubiquitin. For the interpretation of the γ-H2AX and Ki-67 
labeling indices (LI) (nuclear staining in tumoral and non-tumoral hepatocytes), 
more than 1000 cells were counted in random areas of the tissue section and was 
calculated as the percentage of positively stained nuclei.  
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4. DNA extraction and HBV DNA nested PCR 
 
 Twenty patients who were negative for serological tests HBsAg were analyzed for 
the HBV DNA test. Total DNA was extracted from 15 snap frozen human sample 
using a Qiagen QIAamp DNA Mini Kit (Qiagen, Hilden, Germany), and 5 tissue 
slides using a ReliaPrep™ FFPE gDNA Miniprep System (Promega, Madison, WI, 
USA) according to the manufacture‟s instruction. For 15 snap frozen tissues, 
samples were lysed with 180uL of ALT buffer containing 20uL of protease K and 
incubated overnight in a 56°C heat block. After the digestion, 200uL of AL buffer 
and 100% ethanol was added respectively. The solution was transferred to a spin 
column and centrifuged for 1 minute then washed with 500uL of AW1 and AW2 
buffers. To elute the DNA, 200uL of AE buffer was added to the spin column and 
its concentration was quantified using a spectrophotometer NanoDrop (Thermo 
Scientific, Wilmington, DE). For tissue slides, 100% ethanol was added on the slide 
to collect the tissues in a tube and centrifuged for 5 minutes. Ethanol was removed 
and 200uL of lysis buffer was added with 10uL of Proteinase K and incubated 
overnight in a 56°C heat block. After the digestion, 10uL of RNase A was added 
and incubated in a room temperature for 5 minutes. Then, 200uL of BL buffer, 
240uL of 100% ethanol were added and transferred to the spin column and 
centrifuged for 30seconds at 13,000rpm. After washing, DNA was eluted using 
30uL of distilled water. Using the DNA extracts from each sample, HBV DNA 
infection tests were performed by analyzing the presence of HBV genomes. Four 
different in-house nested-PCR amplification assays were followed to detect PreS-S, 
Precore–core, Pol and X HBV genomic regions. As previously described, we 
considered a case to be positive for HBV DNA when at least 2 different viral 
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genomic regions were detected
17
. The primer sets and PCR conditions are listed in 
Table2. PCR was performed with the AccuPower PCR Premix (Bioneer, Seoul, 
Korea) containing 10pM of primers, 250ng of genomic DNA and amplification 
protocol was as follows; 94°C for 5 minutes, 40 cycles of 94°C for 30 seconds, 30 
seconds at each primer‟s annealing temperature and then 30 seconds at 72°C. The 
extension step was performed for 10 minutes at 72°C. A second round of PCR was 
performed for each sample and 1uL of the first round product was added to the 
mixture containing 10pM of second round primers and 18uL of distilled water. The 
second round of PCR was carried out using the same protocol described above. The 
final product and loading star (Dyne Bio, Seongnam, Korea) were loaded on a 2% 
agarose gel (MPBio, Santa Ana, CA, USA) and electrophoresis was performed. Out 
of 20 samples tested, 9 samples showed positivity for at least 2 of the different viral 
genomic regions. 
1Applied in the second round. 
2Annealing temperature. 
 
 
 
 
 
Table 2. Sequences of the primers used for the HBV DNA nested PCR 
Primer 
set 
Sense primers Antisense primers 
Ta
2 
(°C ) 
PreS-S 5′-GGTCACCATATTCTTGGGAA-3′ 5′-AATGGCACTAGTAAACTGAG-3′ 47.4 
PreS-S1 5′-AATCCAGATTGGGACTTCAA-3′ 5′-CCTTGATAGTCCAGAAGAAC-3′ 47.4 
Precore-
core 
5′-GCCTTAGAGTCTCCTGAGCA-3′ 5′-GTCCAAGGAATACTAAC-3′ 47.8 
Precore-
core1 
5′-CCTCACCATACTGCACTCA-3′ 5′-GAGGGAGTTCTTCTTCTAGG-3′ 50.2 
Pol 5′-CGTCGCAGAAGATCTCAATC-3′ 5′-CCTGATGTGATGTTCTCCATG-3′ 50.7 
Pol1 5′-CCTTGGACTCATAAGGT-3′ 5′-TTGAAGTCCCAATCTGGATT-3 45.7 
X 5′-CCATACTGCGGAACTCCTAGC-3 5′-CGTTCACGGTGGTCTCCAT-3′ 57.4 
X1 5′-GCTAGGCTGTGCTGCCAACTG-3 5′-CGTAAAGAGAGGTGCGCCCCG-3′ 59.7 
12 
 
 
 
 
5. Total RNA extraction, cDNA synthesis, and real-time quantitative reverse-
transcriptase PCR 
 
Total RNA was isolated from the snap frozen tissue samples (n = 38) using the 
Qiagen RNA isolation kit (Qiagen, Hilden, Germany) according to the 
manufacture‟s protocol. Briefly, 30mg snap frozen tissue sample were lysed with 
600uL of RLT buffer containing 1% β-mercaptoethanol (Sigma Inc., St. Louis, MO, 
USA) and grinded with a homogenizer. After the disruption, equal volume of 70% 
ethanol was added and then transferred to a RNeasy spin column and centrifuged 
for 15 seconds. The column was washed with 700uL of RW1 buffer and 2 times 
with 500uL of RPE buffer. RNA was eluted using RNase-free water and purity was 
validated using gel electrophoresis and quantified with a spectrophotometer 
NanoDrop (Thermo Scientific, Wilmington, DE). First strand cDNA synthesis was 
performed using a TOPscript 
tm
 cDNA synthesis kit (Enzynomics, Daejeon, Korea) 
and 1ug of total RNA was mixed with 2× RT Buffer, 20× Enzyme Mix, and 
nuclease-free water. The mixtures were incubated for 60 minutes at 37°C, 5 minutes 
at 95°C and then kept at 4°C. The Assay IDs of the primers were as follows: 
GAPDH (Hs_99999905_m1) and IL-6 (Hs_00985639_a1). Real-time quantitative 
RT-PCR was carried out using the Applied Biosystems 7500 Real-Time PCR 
System. The PCR master mix containing TaqMan 2× Universal PCR Master Mix, 
20× TaqMan assay, and RT products in a 20μl reaction volume was processed as 
follows: 95°C for 10 minutes, 40 cycles of 95°C for 15 seconds and then 60°C for 
60 seconds. The signal was collected at the endpoint of every cycle. The mean 
values of the Ct, obtained in triplicate, were used for data analysis. 
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6. Statistical analyses 
 
The data was analyzed using the SPSS version 17.0 software (SPSS Inc., Chicago, 
IL, USA) and presented as mean ± standard deviation. Differences between the 2 
groups were analyzed using the Student‟s t-test, χ2-test, Fisher‟s exact test. 
Univariable survival analyses were performed for overall and disease-free survivals 
using the Kaplan-Meier‟s method and log-rank tests. Statistical significance was 
reached when P ≤ 0.05, and P ≤ 0.1 was reported as a trend. 
 
III. RESULTS 
 
1. Pathological definition and selection of steatohepatitic HCC 
 
HCCs with at least four of the following criteria were classified as steatohepatitic 
HCC: steatosis, tumor cell ballooning, Mallory-Denk bodies formation, pericellular 
fibrosis and inflammation. Twenty-one cases were selected as steatohepatitic HCCs 
according to the above criteria. For comparison, 34 conventional HCCs which did 
not fulfil the criteria of steatohepatitic HCC were selected. The histopathological 
characteristics of 21 steatohepatitic HCCs and 34 conventional HCCs are presented 
in Table 3 and Figure 1. Larger proportions of tumor cells with large droplet 
steatosis (P <0.001) were more frequently seen in steatohepatitic HCCs compared 
to conventional HCCs (e.g., 52.3% vs 0%, based on lipid droplet level „moderate‟ 
and „severe‟, Fig 1A). Tumor cell ballooning (P <0.001) and Mallory-Denk bodies 
(P = 0.017) were also more frequently observed in steatohepatitic HCCs compared 
to conventional HCCs (e.g., 61.9% vs 2.9% and 71.4% vs 38.2%, based on 
ballooning level „marked‟ and Mallory-Denk Bodies „presence‟, respectively, Fig 
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1B). Pericellular fibrosis was also a typical feature of steatohepatitic HCCs (P = 
0.009, Fig 1C); marked pericellular fibrosis was more frequently seen in 
steatohepatitic HCCs (42.8%) compared to conventional HCCs (8.8%) and 
intratumoral inflammation was more frequently seen in steatohepatitic HCCs (P = 
0.022, Fig 1D) compared to conventional HCCs (e.g., 85.7% vs 55.9%, based on 
„mild or moderate‟ presence in inflammation). 
 
 
Figure 1. Histopathological features of steatohepatitic and conventional HCCs. 
Representative images demonstrating the pathological features of steatohepatitic 
HCC showing (A) large droplet steatosis, (B) ballooning change (inset: Mallory-
Denk bodies, highlighted by ubiquitin stain), (C) pericellular fibrosis, (D) 
lymphocytic infiltration and (E, F) conventional HCC (x200) [(A, B, D, E) H&E, 
(C, F) Masson‟s trichrome, (B, inset) ubiquitin]. 
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Abbreviations: SH-HCC, steatohepatitic hepatocellular carcinoma; C-HCC, conventional hepatocellular carcinoma. 
* Fisher‟s exact test and Pearson chi-square. Statistically significant P values are expressed in bold. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. A comparison of the histopathological features between 
steatohepatitic and conventional hepatocellular carcinomas 
  
SH-HCC 
(n=21) 
C-HCC 
(n=34) 
P value* 
Large droplet steatosis (%) 
  
<0.001 
Absent or minimal 1 (4.8%) 21 (61.8%) 
 
Mild 9 (42.9%) 13 (38.2%) 
 
Moderate 7 (33.3%) 0 (0.0%) 
 
Severe 4 (19.0%) 0 (0.0%) 
 
Ballooning (%) 
  
<0.001 
None 0 (0.0%) 6 (17.6%) 
 
Focal 8 (38.1%) 27 (79.4%) 
 
Marked 13 (61.9%) 1 (2.9%) 
 
Mallory-Denk bodies (%) 
  
0.017 
Absent 6 (28.6%) 21 (61.8%) 
 
Present 15 (71.4%) 13 (38.2%) 
 
Pericellular fibrosis (%) 
  
0.009 
None 1 (4.8%) 5 (14.7%) 
 
Focal 11 (52.4%) 26 (76.5%) 
 
Marked 9 (42.8%) 3 (8.8%) 
 
Inflammation (%) 
  
0.022 
Minimal 3 (14.3%) 15 (44.1%) 
 
Mild or moderate 18 (85.7%) 19 (55.9%) 
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2. Other pathological characteristics of steatohepatitic HCC 
 
We next compared the pathological parameters between steatohepatitic and 
conventional HCCs (Table 4). The steatohepatitic HCCs tended to be better 
differentiated compared to conventional HCCs, although statistical significance was 
not reached (major differentiation: P = 0.096, worst differentiation: P = 0.086). 
Other clinico-pathological parameters including tumor size, capsule formation, 
portal vein invasion, microvessel invasion, serosal invasion and satellite nodule 
showed no significant differences between two types of HCCs. In the adjacent non-
tumor liver, NAFLD (including steatosis or steatohepatitis) was more frequently 
seen in steatohepatitic HCC cases compared to that of conventional HCCs (76.2% 
vs 35.2%).  
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Table 4. Pathological characteristics of steatohepatitic and conventional 
hepatocellular carcinomas 
   
SH-HCC C-HCC 
P value* 
(n=21) (n=34) 
Tumor 
Tumor size (cm) 1 
 
3.3 ± 1.5 4.2 ± 3.5 0.308 
Capsule formation (%) 
Complete 2 (9.5%)  9 (26.5%) 0.249 
Partial 11 (52.4%) 17 (50.0%) 
 
None  8 (38.1%)  8 (23.5%) 
 
Major differentiation 
(%) 
Ⅰ  5 (23.8%) 2 (5.9%) 0.096 
Ⅱ 13 (61.9%) 24 (70.6%) 
 
Ⅲ  3 (14.3%)  8 (23.5%) 
 
Worst differentiation 
(%) 
Ⅰ 2 (9.5%) 0 (0.0%) 0.086 
Ⅱ 11 (52.4%) 12 (35.3%) 
 
Ⅲ  8 (38.1%) 21 (61.8%) 
 
Ⅳ 0 (0.0%) 1 (2.9%) 
 
Portal vein invasion (%) 1 (4.8%) 0 (0.0%) 0.382 
Microvessel invasion (%) 8 (38.1%) 15 (44.1%) 0.66 
Serosal invasion (%) 12 (57.1%) 18 (52.9%) 0.761 
Satellite nodule (%) 1 (4.8%)  4 (11.8%) 0.64 
Non- 
tumor 
NAFLD alone (%) 4 (19.1%) 2 (5.8%) 0.010 
NAFLD + B-viral chronic hepatitis (%) 12 (57.1%) 10 (29.4%) 
 
B-viral chronic hepatitis alone (%) 3 (14.3%)  19 (55.9%) 
 
Non-specific reactive hepatitis (%) 2 (9.5%) 3 (8.8%) 
 
Abbreviations: SH-HCC, steatohepatitic hepatocellular carcinoma; C-HCC, conventional hepatocellular carcinoma; 
NAFLD, non-alcoholic fatty liver disease. 
* Fisher‟s exact test, Pearson chi-square and Student‟s t-test. Statistically significant P values are expressed in bold. 
1 Values expressed as mean ± standard deviation. 
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3. Clinical characteristics in steatohepatitic and conventional HCCs 
 
In order to explore whether our cohort of steatohepatitic HCC is associated with 
metabolic syndrome risk factors, we next analyzed the clinical parameters of the 
steatohepatitic and conventional HCCs (Table 5).  The patients with steatohepatitic 
HCC (n = 21) were significantly older compared to conventional HCC patients (n = 
34) (66.7 ± 8.4 years vs 58.5 ± 10.1 years, mean ± SD, P = 0.003). There was no 
significant difference in gender distribution between the two types of HCCs (P = 
0.284).  Steatohepatitic HCC patients had higher BMI compared to that of 
conventional HCC patients (26.0 ± 4.6 kg/m
2
 vs 23.7 ± 2.7 kg/m
2
, mean ± SD, P = 
0.027). The prevalent metabolic syndrome risk factors in steatohepatitic HCC 
patients, compared to those of conventional HCC patients, were central obesity 
(57.1% vs 32.4%, P = 0.012), diabetes (57.1% vs 29.4%, P = 0.041), and 
hypertriglyceridemia (23.8% vs 2.9%, P = 0.028). However, there were no 
significant differences in the prevalence of reduced high-density lipoprotein 
cholesterol (23.8% vs 14.7%, P = 0.387) and hypertension (47.6% vs 41.2%, P = 
0.640) between the two groups. The prevalence of HBV infection and serum 
HBsAg and occult HBV infection did not differ among patients with steatohepatitic 
or those with conventional HCCs (P = 0.300, P = 0.464).Overall, steatohepatitic 
HCC patients more frequently demonstrated metabolic syndrome compared to 
conventional HCC patients (71.4% vs 41.2%, P = 0.029). Moreover metabolic 
syndrome with or without HBV infection did not differ between steatohepatitic and 
conventional HCCs (P = 1.00). 
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Table 5. Clinical characteristics of patients with steatohepatitic and 
conventional hepatocellular carcinomas 
  
SH-HCC C-HCC 
P value* 
(n=21) (n=34) 
Age (years) 1 66.7 ± 8.4 58.5 ± 10.1 0.003 
Sex (male:female) 8:13 18:16 0.284 
Body mass index (kg/m2) 1  26.0 ± 4.6 23.7 ± 2.7 0.027 
Central obesity (%) 2 12 (57.1%) 11 (32.4%) 0.012 
Low HDL cholesterol (%)3  5 (23.8%)  5 (14.7%) 0.387 
Diabetes (%)3 12 (57.1%) 10 (29.4%) 0.041 
Hypertension (%)3 10 (47.6%) 14 (41.2%) 0.64 
Hypertriglyceridemia (%)3  5 (23.8%)  1 (2.9%) 0.028 
HBV infection (%) 15 (71.4%) 29 (85.3%) 0.300 
Serum HBsAg (+) 11 (52.4%) 24 (70.6%) 0.464 
Occult HBV infection4  4 (19.1%)  5 (14.7%)  
Metabolic syndrome (%)5       15 (71.4%) 14 (41.2%) 0.029 
MS (+)/HBV(-)  4 (19.0%) 3 (8.8%) 1.000 
MS (+)/HBV(+) 11 (52.4%) 11 (32.4%)  
Abbreviations: SH-HCC, steatohepatitic hepatocellular carcinoma; C-HCC, conventional hepatocellular carcinoma; 
HDL, high-density lipoprotein; HBV, hepatitis B virus; hepatitis B virus surface antigen, HBsAg; MS, metabolic 
syndrome. 
* Fisher‟s exact test, Pearson chi-square and Student‟s t-test. Statistically significant P values are expressed in bold. 
1 Values expressed as mean ± standard deviation. 
2As defined by the International Diabetes Federation (IDF) ethnicity waist circumference criteria. Central obesity 
(waist circumference >90 cm in men and >80 cm in women). 
3As defined by the US National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) 
guidelines. Low HDL cholesterol (<40 mg/dL in men and <50 mg/dL in women), diabetes (elevated fasting plasma 
glucose levels ≥100 mg/dL or current use of anti-diabetic medication), hypertension (systolic blood pressure ≥130 
mmHg or diastolic blood pressure ≥85 mmHg or current use of blood pressure medication) and 
hypertriglyceridemia (elevated serum triglycerides ≥150 mmHg or current use of antidyslipidemia medication). 
4 Occult HBV infection was considered positive when at least 2 different viral genomic regions (PreS-S, Precore–
core, Pol and X HBV) were detected. 
5 The metabolic syndrome was defined by at least two of the five followings: central obesity, low HDL, diabetes, 
hypertension and hypertriglyceridemia. 
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4. Increased numbers of activated hepatic stellate cells in steatohepatitic HCC 
 
The number of activated hepatic stellate cells was compared between steatohepatitic 
and conventional HCCs, by performing an immunohistochemical stain for α-SMA 
which is expressed in activated hepatic stellate cells (Fig. 2A, B). Interestingly, the 
number of activated hepatic stellate cells was higher in the tumor region of 
steatohepatitic HCCs compared to conventional HCCs (P = 0.049). In contrast, in 
the non-tumor region, the number of activated hepatic stellate cells showed no 
statistically significant difference between the two types of HCC (P = 0.358). In 
normal control livers, α-SMA positive stellate cells were rarely detected in the 
perisinusoidal spaces, and significantly lower than the non-neoplastic livers of both 
steatohepatitic and conventional HCCs (P = 0.001 for both). 
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Figure 2. Activated hepatic stellate cells are increased in the tumor region of 
steatohepatitic HCC. (A) Representative H&E stain images of tumor and non-
tumor regions of steatohepatitic HCC (SH-HCC) and conventional HCCs (C-HCC) 
and normal liver (NL) in the upper panels, and their representative 
immunohistochemical stains for α-SMA (brown) in the lower panels. [H&E, 
Original magnification, x200 (Tumor), x100 (Non-Tumor and NL); α-SMA, x400]. 
(B) The numbers of activated hepatic stellate cells were counted, using 20 randomly 
selected high power fields (x400) from the tumor and non-tumor regions of 
steatohepatitic and conventional HCCs, and compared to those from normal control 
liver. SH-HCC, steatohepatitic HCC; C-HCC, conventional HCC; NL, Normal 
control liver. 
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5. Increased numbers of activated hepatic stellate cells, expressing 
senescence-associated proteins and senescence-associated secretory 
phenotype (SASP) factor in the tumor region of steatohepatitic HCC 
Our present finding that activated hepatic stellate cells were more frequently found 
in the tumor region of steatohepatitic HCC compared to conventional HCC 
prompted us to investigate whether a senescence-associated proteins and SASP of 
activated hepatic stellate cells is related to the development of steatohepatitic HCC. 
Activated hepatic stellate cells undergoing senescence generate DNA damage 
signals, in addition to the expression of cell cycle arrest markers such as p21
Waf1/Cip1
. 
Therefore, we examined p21
Waf1/Cip1
 and γ-H2AX, a DNA damage marker13, in 
activated stellate cells, to explore whether senescence-associated protein expression 
is involved in steatohepatitic HCC.  There was occasional co-expression of 
p21
Waf1/Cip1
 and cytoplasmic α-SMA in stellate cells, and it was significantly higher 
in the tumor region of steatohepatitic HCCs compared to that of conventional HCCs 
(5.9% vs 4.2%, P = 0.038) (Fig. 3A). Next, we performed immunofluorescence 
staining of γ-H2AX (red fluorescence) and α-SMA (green fluorescence), in order to 
examine whether hepatic stellate cell activation in steatohepatitic HCCs is 
associated with DNA damage. Nuclear γ-H2AX was occasionally detected together 
with cytoplasmic α-SMA expression in the tumor region of steatohepatitic HCCs. 
The co-expression of γ-H2AX and α-SMA in the hepatic stellate cells was also 
higher in tumor region of steatohepatitic HCCs than conventional HCCs (27.3% vs 
19.4%, P = 0.066) (Fig. 3B). To compare the proliferation activity of stellate cells 
between two types of HCC, a double-immunofluorescence staining was performed 
with Ki-67 (green fluorescence), a proliferation marker, and α-SMA (red 
fluorescence) (Fig. 3C). There were no significant differences in Ki-67/α-SMA co-
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staining between the steatohepatitic and conventional HCCs (4.7% vs 4.1%, P = 
0.775) (Fig. 3C). These findings indicate that activation of hepatic stellate cells 
accompanied with senescence-associated protein expression, including DNA 
damage and p21
Waf1/Cip1
 are more involved in steatohepatitic HCCs compared to 
conventional HCCs.  
As IL-6 is one of the major SASP factors in hepatic inflammation
13
, which is one of 
key features of steatohepatitic HCC, we examined the correlation between hepatic 
stellate cell activation and IL-6 expression. Immunohistochemical staining showed 
IL-6 expression in tumor stromal region of steatohepatitic and conventional HCCs 
(Fig. 3D). When IL-6 staining area and intensity was semiquantitatively analyzed, 
we found that IL-6 was more highly expressed in the tumor region of steatohepatitic 
HCCs compared to conventional HCCs (P = 0.009) (Fig. 3D). Double 
immunofluorescence staining for IL-6 and α-SMA revealed that IL-6 (seen as red 
signals dispersed between stromal cell components) was either co-expressed in α-
SMA-expressing cells or expressed alone without the green fluorescence (Fig. 3E). 
Specifically, IL-6/α-SMA co-expression was more frequently seen in the tumor 
regions of steatohepatitic HCCs than in conventional HCCs (29.3% vs 7.0%, P = 
0.048) (Fig 3E). These findings indicate that SASP factor IL-6 expression occurs 
more frequently in steatohepatitic HCC. Collectively, steatohepatitic HCC 
expresses a SASP factor (IL-6) in the activated hepatic stellate cells, accompanied 
by the generation of senescent phenotype (p21
Waf1/Cip1
 and γ-H2AX). 
Furthermore, we examined the senescence-associated protein expressions in tumoral 
hepatocytes between the two types HCCs. However, there was no difference in 
p21
Waf1/Cip1, γ-H2AX-LI and Ki-67-LI expression between steatohepatitic and 
conventional HCCs in tumoral hepatocytes (P = 0.428, P = 0.283, P = 0.119, 
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respectively) (Fig. 4A~C). IL-6 mRNA levels, which were evaluated using whole 
tumor tissue were not different between the two groups (P = 0.486) (Fig. 4D). 
 
 
Figure 3. Increased numbers of activated hepatic stellate cells expressing 
senescence-associated proteins and senescence-associated secretory phenotype 
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(SASP) factor in the tumor region of steatohepatitic HCC. (A) Representative 
double immunohistochemistry images of the sections showing co-staining for 
p21
Waf1/Cip1
 (blue) and α-SMA (brown) and box plot demonstrating the frequency of 
co-stained cells. Representative double immunofluorescence images and box plot 
demonstrating frequency of co-stained cells for (B) γ-H2AX (red fluorescence) and 
α-SMA (green fluorescence) (C) Ki-67 (green fluorescence) and α-SMA (red 
fluorescence) (E) IL-6 (red fluorescence) and α-SMA (green fluorescence) in 
tumor regions of the steatohepatitic HCC (SH-HCC) and conventional HCC (C-
HCC). Nuclei were stained with DAPI. The merged fluorescence images of γ-
H2AX/α-SMA, Ki67/α-SMA and IL-6/ α-SMA in the boxed areas are further 
magnified (inset). (original magnification x400). (D) Representative 
immunohistochemistry images for IL-6 (brown, original magnification x200) and 
protein expression level of IL-6 were compared in steatohepatitic and conventional 
HCCs. SH-HCC and SH, steatohepatitic HCC; C-HCC and C, conventional HCC. 
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Figure 4. Senescence-associated proteins in the tumoral hepatocytes of 
steatohepatitic and conventional HCCs. (A) Representative double 
immunohistochemistry images of the sections showing p21
Waf1/Cip1
 (blue) and α-
SMA (brown) and protein expression of p21
Waf1/Cip1
 in tumoral hepatocytes were 
compared. Representative immunofluorescence for (B) γ-H2AX (red fluorescence) 
and α-SMA (green fluorescence) and box plot demonstrating γ-H2AX-LI in tumoral 
hepatocytes and (C) Ki-67 (green fluorescence) and α-SMA (red fluorescence) and 
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box plot demonstrating Ki-67-LI in tumoral hepatocytes of steatohepatitic HCC 
(SH-HCC) and conventional HCC (C-HCC) were compared. Nuclei were stained 
with DAPI. The merged fluorescence images of γ-H2AX/α-SMA and Ki67/α-SMA 
in the boxed areas are further magnified (inset). (original magnification x400). (D) 
A comparison between the mRNA expression levels of IL-6 in the tumor region of 
steatohepatitic (n=14) and conventional HCCs (n=24). SH-HCC and SH, 
steatohepatitic HCC; C-HCC and C, conventional HCC. 
 
6. Senescent-associated proteins and senescence-associated secretory 
phenotype (SASP) factor in activated hepatic stellate cells in the non-tumor 
region of steatohepatitic and conventional HCCs and normal control livers 
We further compared the senescence-associated proteins (p21
Waf1/Cip1 
and γ-H2AX) 
and SASP expression in the activated hepatic stellate cells and hepatocytes in the 
non-tumor region of steatohepatitic and conventional HCCs and normal control 
livers. As shown in Fig 5A, we found significant increase in the co-expression of 
nuclear p21
Waf1/Cip1
 and cytoplasmic α-SMA in stellate cells in the non-tumor region 
of steatohepatitic HCCs compared to conventional HCCs (2.0% vs 0.73%, P = 
0.019) (Fig 5A). Similarly to p21
Waf1/Cip1
, the co-staining of γ-H2AX and α-SMA in 
the activated hepatic stellate cells was also higher in non-tumor regions of 
steatohepatitic HCCs than conventional HCCs (7.6% vs 3.8 %, P = 0.023) (Fig 5B). 
No differences were seen for Ki-67/α-SMA co-staining between the steatohepatitic 
and conventional HCCs in the non-tumor regions (0.8% vs 1.1 %, P = 0.389) (Fig 
5C). The expression of IL-6 were more highly expressed in the non-tumor region of 
steatohepatitic HCC compared to that of conventional HCC; however, significance 
was not reached (P = 0.094) (Fig 5D). There was no difference in IL-6/α-SMA co-
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expression in the non-tumor regions of these two types (5.9% vs 5.4%, P = 0.299) 
(Fig 5E). When the senescence-associated protein expression of p21
Waf1/Cip1, γ-
H2AX-LI and Ki-67-LI was compared in the non-tumoral hepatocytes between 
steatohepatitic and conventional HCCs, there was no significant difference in their 
expression (P = 0.208, P = 0.277, P = 0.927, respectively) (Fig 6A~C). 
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Figure 5. Senescence-associated proteins and senescence-associated secretory 
phenotype (SASP) factor in the activated hepatic stellate cells in the non-tumor 
region of steatohepatitic and conventional HCCs. Representative double 
immunohistochemistry images of the sections showing co-staining for p21
Waf1/Cip1
 
(blue) and α-SMA (brown) and box plot demonstrating the frequency of co-stained 
cells. Representative double immunofluorescence images and box plot 
demonstrating frequency of co-stained cells for (B) γ-H2AX (red fluorescence) and 
α-SMA (green fluorescence) (C) Ki-67 (green fluorescence) and α-SMA (red 
fluorescence) (E) IL-6 (red fluorescence) and α-SMA (green fluorescence) in non-
tumor regions of the steatohepatitic HCC (SH-HCC) and conventional HCC (C-
HCC). Nuclei were stained with DAPI. The merged fluorescence images of γ-
H2AX/α-SMA, Ki67/α-SMA and IL-6/ α-SMA in the boxed areas are further 
magnified (inset). (original magnification x400). (D) Representative 
immunohistochemistry images for IL-6 (brown, original magnification x200) and 
protein expression level of IL-6 were compared in the non-tumor regions of 
steatohepatitic and conventional HCCs. SH-HCC and SH, steatohepatitic HCC; C-
HCC and C, conventional HCC. 
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Figure 6. Senescence-associated proteins in the non-tumoral hepatocytes of 
steatohepatitic and conventional HCCs. (A) Representative double 
immunohistochemistry images of the sections showing p21
Waf1/Cip1
 (blue) and α-
SMA (brown) and protein expression of p21
Waf1/Cip1
 in non-tumoral hepatocytes 
were compared. Representative immunofluorescence for (B) γ-H2AX (red 
fluorescence) and α-SMA (green fluorescence) and box plot demonstrating γ-
H2AX-LI in non-tumoral hepatocytes and (C) Ki-67 (green fluorescence) and α-
SMA (red fluorescence) and box plot demonstrating Ki-67-LI in non-tumoral 
hepatocytes of steatohepatitic HCC (SH-HCC) and conventional HCC (C-HCC) 
were compared. Nuclei were stained with DAPI. The merged fluorescence images 
of γ-H2AX/α-SMA and Ki67/α-SMA in the boxed areas are further magnified 
(inset). (original magnification x400). SH-HCC and SH, steatohepatitic HCC; C-
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HCC and C, conventional HCC. 
In normal control livers (n=5), only one case showed co-staining of p21
Waf1/Cip1, γ-
H2AX in the activated hepatic stellate cells and Ki-67, IL-6 were not detected. (Fig. 
7A~F). 
 
Figure 7. Senescence-associated proteins and senescence-associated secretory 
protein (SASP) factor in the normal control liver. (A) Representative H&E and 
(B) double immunohistochemistry image of the sections showing p21
Waf1/Cip1
 (blue) 
and α-SMA (brown). (C) Representative double immunofluorescence images of the 
sections positive for γ-H2AX (red fluorescence) and α-SMA (green fluorescence), 
(D) Ki-67 (green fluorescence) and α-SMA (red fluorescence) and (F) IL-6 (red 
fluorescence) and α-SMA (green fluorescence) in normal control liver. Nuclei were 
stained with DAPI. The merged fluorescence images of γ-H2AX/α-SMA, Ki67/α-
SMA and IL-6/ α-SMA in the boxed areas are further magnified (inset). (original 
magnification x400). (E) Representative immunohistochemistry images for IL-6 
(brown, original magnification x200).  
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7. Survival analysis in steatohepatitic and conventional HCCs 
 
To explore the prognostic significance of steatohepatitic HCCs, we analyzed patient 
survival after surgical resection. One patient from conventional HCC who had liver 
transplantation was excluded from the survival analysis. The median follow-up time 
after surgical resection was 30.5 months (range, 1~73). Kaplan-Meier plots revealed 
no significant difference in both disease-free (P = 0.602) and overall survivals (P = 
0.709) between steatohepatitic (n = 21) and conventional HCCs (n = 33) (Fig. 8 A, 
B).  
 
 
Figure 8. Survival analysis results. Kaplan–Meier‟s plot analysis for (A) disease-
free and (B) overall survival in steatohepatitic HCC (SH-HCC) and conventional 
HCC (C-HCC). SH-HCC, steatohepatitic HCC; C-HCC, conventional HCC. 
 
IV. DISCUSSION 
 
The steatohepatitic variant of HCC has been reported to be more frequently 
associated with metabolic syndrome and NAFLD compared to conventional HCCs
7-
9
. Due to changes in lifestyle and diet, metabolic syndrome is increasing in Asia 
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including Korea as well as Western countries, and in the near future it is expected to 
exceed viral hepatitis as an etiology of chronic liver disease
18
. Most studies with 
steatohepatitic HCC have mainly dealt with HCV, and its relation with HBV or 
molecular pathogenesis remains unclear. In this study we focused on HCC patients 
with non-C viral, non-alcoholic and non-autoimmune hepatitis etiologies, and 
performed HBV DNA test to more specifically understand the association between 
steatohepatitic HCC with HBV and metabolic syndrome.  
In this study, steatohepatitic HCCs showed older age, increased metabolic 
syndrome risk factors, better differentiation of tumor and more prevalent NAFLD in 
non-tumor regions compared to conventional HCCs, and it was consistent with 
previous reports
7-9
. Interestingly, we found that prevalence of HBV infection did not 
differ between the two types of HCCs. In addition, most of the steatohepatitic HCCs 
demonstrated NAFLD with HBV in the non-tumor regions. Of note, previous 
studies in in vitro and transgenic mice have shown that HBV genome, hepatitis B 
virus protein X (HBx), can up-regulate lipogenic genes and promote steatosis
19, 20
. 
Furthermore, HBx transgenic mice fed a high fat diet stabilizes HBx protein using 
fatty acid and promotes steatohepatitis
21
. HBV infection has also been shown to 
alter bile acid and cholesterol metabolism
22
. Further studies are needed to 
understand the complex interplay between HBV infection and its effect on 
metabolic syndrome and neoplastic hepatocytes.  
In normal liver, hepatic stellate cells are mostly quiescent retinoid-storing cells. 
Upon liver injury, hepatic stellate cells become activated to become highly 
fibrogenic cells and secrete various cytokines and interact with hepatocytes and the 
microenvironment
23
. Recent research showed that dietary or genetically induced-
obese mice had changes in the microbiome and its metabolite promoted SASP in 
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hepatic stellate cells that led to HCC development.
13
  When cells undergo 
senescence, they develop inflammatory cytokines, chemokines and proteases also 
known as SASP
24
. Some SASP factors, such as IL-6 are known to be associated 
with NAFLD and obesity-associated cancer
25, 26
. In the present study, we 
demonstrated increased activated hepatic stellate cells in tumor region of 
steatohepatitic HCCs compared to conventional HCC. In addition, activated hepatic 
stellate cells showed increased expression of cellular senescence marker such as p21
 
Waf1/Cip1
 and DNA damage marker γ-H2AX in steatohepatitic HCCs both in tumor 
and non-tumor regions compared to conventional HCC. To examine if this response 
further correlated with SASP factor, we performed IL-6 immunohistochemistry and 
found increased expression of IL-6 in the steatohepatitic HCCs. To see whether 
activated hepatic stellate cells secrete IL-6, we performed double 
immunofluorescence and found that these stellate cells also secrete IL-6 and this 
was more prominent in steatohepatitic HCCs compared to conventional HCCs. 
Unlike in the tumor, we did not see differences in the number of activated hepatic 
stellate cells and IL-6/α-SMA co-expressing cells in the non-tumor regions between 
two types of HCCs. Therefore, it is suggested that activated hepatic stellate cells 
showing features of SASP could play important roles in the pathogenesis of 
steatohepatitic HCC.  
There are several limitations to our study. The current study was retrospective in 
design and some of the metabolic syndrome related data were missing.  In addition, 
even though we found increased IL-6 expression in steatohepatitic HCCs, there 
were no significant differences in the clinicopathological factors related to tumor 
aggressiveness or survival between steatohepatitic and conventional HCCs unlike 
the previous report by Shibahara et al
9
. Prospective studies based on large number 
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of cases are needed to further understand the interplay between SASP factor and its 
effect on the biological behavior of steatohepatitic HCC. 
 
V. CONCLUSION 
 
Steatohepatitic HCC showed higher incidence of metabolic syndrome with or 
without HBV than conventional HCC, and non-tumoral liver of steatohepatitic HCC 
also showed higher incidence of NAFLD compared to that of conventional HCC. 
Activated hepatic stellate cells expressing p21
Waf1/Cif1, γ-H2AX and IL-6 were more 
frequently found in tumoral region of steatohepatitic HCC compared to 
conventional HCC. Non-tumoral liver of steatohepatitic HCC also showed higher 
number of activated stellate cells expressing γ-H2AX and p21Waf1/Cif1 compared to 
that of conventional HCC. Therefore, steatohepatitic HCC is suggested as a 
distinctive variant of HCC, which is closely associated with metabolic syndrome 
with or without chronic B viral hepatitis. Activated hepatic stellate cells with SASP 
signature is considered to be important in the pathogenesis of steatohepatitic HCC. 
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< ABSTRACT (IN KOREAN)> 
 
지방간염성 간암에서 활성화된 간 성상세포의  
노화활성인자 발현 
 
<지도교수 박 영 년> 
 
연세대학교 대학원 의과학과 
 
이 지 산 
 
최근 종양 내에 지방간염의 병리학적 소견을 보이는 간암인 지방간염성 
간암 (steatohepatitic HCC)이 대사증후군과 함께 비알코올성 지방간염을 
동반한 C형 간염 간암환자에서 보고되었다. 한국을 비롯한 동양에서 최
근 대사증후군의 발생이 급격히 증가하고 있으며, 또한 만성 B형간염의 
발생빈도가 높은 실정이나, 대사증후군을 동반한 만성 B형 간염 환자에
서의 지방간염성 간암의 발생 및 분자병리학적 특징은 아직 밝혀지지 않
았다. 본 연구에서는 C형 간염, 알코올성 간염, 그리고 자가면역성 간염
을 제외한 간암환자에서 지방간염성 간암 (SH-HCC) 21명과 전형적인 
간세포암종의 병리학적 소견을 보이는 간암 환자군 (C-HCC) 34명을 선
별하여 분자병리학적 특성을 비교하였다. B형 간염의 유무는 혈청 
HBsAg 검사 및 간조직에서의 HBV DNA에 대한 이중 중합효소 연쇄반
응으로 검색하였으며, 특히 활성화된 간 성상세포에서의 노화활성인자 발
현에 중점을 두어 분자병리학적 특성을 비교하였다. 이중 면역염색 및 면
역형광 염색방법을 이용하여 α-smooth muscle actin (α-SMA), 
p21Waf1/Cip1, γ-H2AX 그리고 IL-6에 대한 발현을 비교하였다. SH-HCC
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군에서 C-HCC군에 비해 발생연령이 높았으며, BMI, 당뇨, 복부비만, 고
지혈증 및 비알코올성 지방간의 발생빈도가 더 높았다 (P <0.05). SH-
HCC군에서 C-HCC군에 비하여 대사증후군의 발생이 높았으며 (P = 
0.029), 반면 만성 B형간염 발생은 두 군간의 차이를 보이지 않았다. 
SH-HCC의 종양내에서 활성화된 간성상세포가 C-HCC에 비하여 더 자
주 관찰되었으며, 활성 간성상세포에서 발현하는 p21Waf1/Cip1, IL-6 (P 
<0.05) 및 γ-H2AX (P = 0.066)의 발현정도도 SH-HCC에서 의 C-
HCC에 비하여 높았다. 간의 비종양 부위에서도 p21Waf1/Cip1, γ-H2AX 를 
발현하는 활성화된 간 성상세포가 SH-HCC에서 C-HCC의 비 종양 부
분에 비해 더 많았다(P <0.05). 활성화된 간 성상세포에서의 Ki-67 발
현은 종양, 비 종양 부분에서 두 군간에 차이가 없었다.  
이상의 소견으로 SH-HCC은 대사증후군과 연관된 HCC의 특징적인유형
으로 생각되며, B형간염 환자에서도 대사증후군이 동반될 경우 SH-HCC
이 발생이 증가된다.  또한 SH-HCC 간암발생에 활성화된 간 성상세포
에서에서 발현하는 노화인자 (p21Waf1/Cif1, γ-H2AX) 및 노화활성인자 
(IL-6)가 중요한 역할을 할 것으로 생각한다. 
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